Brain Tumor Diagnostics Market: Market Size & Forecast 2026

The brain tumor diagnostics market encompasses the technologies, reagents, and services used to identify and classify tumors of the brain and central nervous system. It spans structural imaging modalities such as MRI and CT, nuclear medicine techniques like PET, histopathology and immunohistochemistry, and emerging molecular and liquid biopsy assays. The market sits at the intersection of medical imaging, oncology diagnostics, and neuro-oncology, and serves hospitals, cancer centers, ambulatory imaging providers, and reference laboratories worldwide.

• •Estimated global value of approximately $3.04 billion in 2025, with a projected CAGR near 7.97%.
• •Independent forecasts range roughly from $1.7 billion to $4.8 billion depending on whether therapeutics, drugs, or diagnostics-only scope is measured.
• •Demand is driven by both newly diagnosed brain tumor cases and the need for monitoring during and after treatment.

Rising global incidence of primary and metastatic brain tumors, combined with aging populations in major markets, is expanding the patient pool that requires diagnostic workups. Advances in imaging hardware, including high-field MRI and advanced PET tracers, are improving detection rates and enabling earlier diagnosis. At the same time, AI-driven image analysis, next-generation sequencing of tumor tissue, and blood-based liquid biopsy tests are creating new diagnostic submarkets with premium pricing and faster turnaround times.

• •Increasing brain tumor incidence and aging demographics are widening the addressable patient base.
• •Adoption of AI-based radiology tools and molecular diagnostics is improving accuracy and supporting premium-priced test menus.
• •Greater healthcare expenditure and imaging infrastructure investment in emerging economies are expanding access to advanced diagnostics.

By diagnostic technique, the market is typically segmented into imaging (MRI, CT, PET), biopsy and histopathology, molecular diagnostics, and emerging liquid biopsy approaches. By end user, demand is concentrated in hospitals and specialty cancer centers, with growing contributions from diagnostic laboratories and ambulatory imaging facilities. Geographically, North America leads on the back of advanced imaging installed bases and high per-capita healthcare spending, while Asia-Pacific is the fastest-growing region due to expanding healthcare infrastructure in China, India, Japan, and South Korea.

• •Imaging remains the largest diagnostic segment, with molecular and liquid biopsy representing the fastest-growing sub-markets.
• •North America holds the leading regional share, followed by Europe; Asia-Pacific is projected to grow at the highest CAGR.
• •Hospitals account for the majority of end-user demand, but independent diagnostic labs are gaining share.

What are the recent trends and outlook?

Artificial intelligence is the single most disruptive force in the market, with deep-learning models increasingly approved to assist radiologists in detecting, segmenting, and grading brain tumors on MRI and CT scans. Liquid biopsy, including circulating tumor DNA and cell-free DNA assays, is emerging as a less invasive complement to surgical tissue sampling for diagnosis and treatment monitoring. Looking ahead, the convergence of advanced imaging, genomics, and AI decision support is expected to support continued mid- to high-single-digit growth through the early 2030s, with precision neuro-oncology expanding the role of diagnostics in guiding targeted therapies.

• •AI-assisted imaging interpretation is moving from research into routine clinical use for brain tumor detection and grading.
• •Liquid biopsy assays for brain tumors are advancing through clinical validation and could reduce reliance on invasive surgical biopsies.
• •Integration of imaging, genomics, and AI is enabling more personalized treatment planning, supporting sustained market growth into the next decade.